Topic 372: development and validation of non-mouse reagents to enable preclinical development of novel therapeutics
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91020C00018
- Awardee
-
Avantgen Inc. UEI WLNHKNPNT2M7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,995,852
Award facts
- Opportunity
-
- BAA75N91019R00032 Solicitation number
- Contract value 100% obligated
- $1,995,852.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,995,852 |
About this award
This is a $1,995,852.00 Firm Fixed Price SBIR Phase II contract awarded by the National Cancer Institute (NCI) to Avantgen Inc., a small business based in San Diego, California. The contract is for the "Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics" under Topic 372. The goal is to develop high-affinity, highly specific rabbit monoclonal antibodies against an expanded panel of 26 canine biomarkers to facilitate the use of dogs with naturally occurring cancers as a better model system for evaluating novel cancer immunotherapies. Avantgen will also optimize a caninized anti-canine-PD-1 antibody as a potential canine immunotherapeutic and conduct a pilot study in pet dogs with lymphoma. Duke University is a major subcontractor supporting this effort.
Quick answers
Who was awarded contract 75N91020C00018?
75N91020C00018 was awarded to Avantgen Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2020.
How much is contract 75N91020C00018 worth?
The government has obligated $1,995,852 on 75N91020C00018.
Was contract 75N91020C00018 competed?
The extent of competition for 75N91020C00018 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award